Subcutaneous semaglutide more than doubles the likelihood of NASH resolution without fibrosis progressionSemaglutide shows promise for treating fatty liver disease and NASH

This meta-analysis evaluated the efficacy and tolerability of subcutaneous semaglutide compared to placebo in an adult population (aged 18 years and older) diagnosed with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). The study utilized a multi-modal diagnostic approach, including imaging, histology, and biochemical markers to confirm patient eligibility. The primary objective was to assess semaglutide's impact on biochemical, histologic, metabolic, and safety outcomes in this specific population.

The intervention consisted of subcutaneous semaglutide administered against a placebo control. While the specific dosing protocols were not detailed in the summary data, the analysis focused on the overall comparative efficacy of the medication for patients with liver disease. The primary outcome measures included changes in liver enzymes (aspartate aminotransferase), NASH resolution without fibrosis progression, and improvements in fibrosis stage.

Regarding biochemical markers, semaglutide significantly reduced aspartate aminotransferase levels by -6.72 U/L (95% CI -11.79 to -1.64; P =.009). In terms of histologic outcomes, the administration of semaglutide more than doubled the likelihood of NASH resolution without fibrosis progression (RR = 2.14; 95% CI 1.44-3.17; P =.0002). However, the impact on fibrosis stage improvement was not statistically significant (RR = 1.14; 95% CI 0.63-2.05; P =.67), indicating that while NASH may resolve, the progression of underlying fibrosis is less certain.

Metabolic outcomes also favored semaglutide. Patients experienced substantial weight loss of -6.99% (95% CI -13.92 to -0.06; P =.05). Additionally, glycated hemoglobin levels were improved by -1.29% (95% CI -1.46 to -1.13; P <.00001). These findings suggest that semaglutide provides a multi-faceted benefit for patients with metabolic and liver comorbidities.

Safety and tolerability data indicated that gastrointestinal adverse events occurred more frequently in the semaglutide group compared to placebo. However, serious adverse events were comparable between the two groups (95% CI 0.81-1.41; P =.64; P =.65). While treatment discontinuation occurred more frequently with semaglutide, the overall safety profile was considered acceptable for clinical use.

These results align with broader trends in incretin-based therapies where metabolic improvements often correlate with liver health. However, the specific lack of statistical significance regarding fibrosis progression highlights a critical gap in current evidence. The study notes that while semaglutide shows promising efficacy for NASH resolution and meaningful metabolic improvement, its specific role in reversing established fibrosis remains an area requiring further investigation.

Methodological limitations include the uncertainty regarding the effect on fibrosis and the need for longer-term, adequately powered trials to clarify the role of semaglutide specifically in NAFLD/NASH treatment. Clinicians can consider semaglutide as a promising option for NASH resolution and metabolic improvement, but should manage patient expectations regarding the reversal of advanced fibrosis. Questions remain regarding the long-term durability of these improvements and the specific impact on different stages of liver disease.